A proliferation-inducing ligand (APRIL): The development of antagonistic agents as potential therapeutics and deciphering the role of heparan sulphate proteoglycans (HSPGs) in APRIL signalling

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 501-506

  Kimberley, Fiona ^a   Guadagnoli, Marco ^a   Van Eenennaam, Hans ^b   Medema, Jan Paul ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; ATACICEPT; MONOCLONAL ANTIBODY; PROTEOHEPARAN SULFATE;

AUTOIMMUNE DISEASE; CONFERENCE PAPER; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; METABOLISM; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MICE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 79954446951     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_52     Document Type: Conference Paper

References (33)

1. Belnoue E, Pihlgren M et al (2008) APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early life bone marrow stromal cells. Blood 111(5):2755-2764. Epub 2008 Jan 7
2. Benson MJ, Dillon SR et al (2008) Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180(6):3655-3659
3. Bossen C, Cachero TG et al (2008) TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111(3):1004-1012. Epub 2007 Oct 17
4. Castigli E, Scott S et al (2004) Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A 101(11):3903-3908
5. Dillon SR, Gross JA et al (2006) An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5(3):235-246
6. DingW, Ju S et al (2009) Reduced APRIL expression induces cellular senescence via a HSPGdependent pathway. Pathol Oncol Res 15(4):693-701. Epub 2009 May 26
7. DingW,Wang J et al (2009) APRIL knockdown suppresses migration and invasion of human colon carcinoma cells. Clin Biochem 42(16-17):1694-1698. Epub 2009 Jun 30
8. Gatto B (2008) Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 9(11):1216-1227
9. Hahne M, Kataoka T et al (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188(6):1185-1190
10. Hatzoglou A, Roussel J et al (2000) TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 165(3):1322-1330
11. Hendriks J, Planelles L et al (2005) Heparan sulfate proteoglycan binding promotes APRILinduced tumor cell proliferation. Cell Death Differ 12(6):637-648
12. Huard B, McKee T et al (2008) APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 118(8):2887-2895.
13. Erratum in: J Clin Invest. 2010 Apr;120(4):1362
14. Ingold K, Zumsteg A et al (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201(9):1375-1383
15. Kimberley FC, Hahne M et al (2009) APRIL hath put a spring of youth in everything. Relevance of APRIL for survival. J Cell Physiol 218(1):1-8
16. Kimberley FC, Medema JP et al (2009) APRIL in B-cell Malignancies and Autoimmunity. Results Prob Cell Differ 49:161-182. Review
17. Kimberley FC, van Bostelen L et al (2009) The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. Faseb J 23(5):1584-1595
18. Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G (2002) Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 108(3):383-394
19. Mackay F, Silveira PA et al (2007) B cells and the BAFF/APRIL axis: Fast-forward on autoimmunity and signaling. Curr Opin Immunol 19(3):327-336
20. Massacand JC, Kaiser P et al (2008) Intestinal bacteria condition dendritic cells to promote IgA production. PLoS One 3(7):e2588
21. Moreaux J, Cremer FW et al (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106(3):1021-1030
22. Moreaux J, Legouffe E et al (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8):3148-3157
23. Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF, Klein B (2009) APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83(2):119-129. Epub 2009 May 30
24. Planelles L, Carvalho-Pinto CE et al (2004) APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6(4):399-408
25. Planelles L, Castillo-Gutierrez S et al (2007) APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: Prognostic relevance of APRIL for survival. Haematologica 92(9):1284-1285
26. Pradet-Balade B,Medema JP et al (2002) An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. Embo J 21(21):5711-5720
27. Rennert P, Schneider P et al (2000) A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 192(11):1677-1684
28. Sakurai D, Hase H et al (2007) TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 109(7):2961-2967
29. Schneider P, Takatsuka H et al (2001) Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 194(11):1691-1697
30. Swee LK, Ingold-Salamin K et al (2009) Biological activity of ectodysplasin a is conditioned by its collagen and heparan sulfate proteoglycan-binding domains. J Biol Chem 284(40):27567-27576. Epub 2009 Aug 5
31. Tezuka H, Abe Y et al (2007) Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 448(7156):929-933
32. Xia XZ, Treanor J et al (2000) TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 192(1):137-143
33. Yaccoby S, Pennisi A et al (2008) Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22:406-413